STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial
2024年2月27日 - 6:01AM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the
Company”), a medical technology company dedicated to developing,
commercializing and marketing innovative products for the treatment
of dermatologic conditions, today announced the successful
amendment of its credit and security agreement with MidCap
Financial Trust (“MidCap”) effective February 20, 2024.
This amendment, recognized as Amendment No. 4 (“Amendment”),
removes the minimum revenue requirements for 2023 and introduces
future financial covenants. The Amendment ensures alignment with
the Company’s current and future business projections by supporting
operational and capital needs.
Dolev Rafaeli, STRATA’s Vice Chairman and Chief Executive
Officer, remarked, “This amendment signifies the strength of our
partnership with MidCap Financial Trust and our lenders. Their
support enables us to continue advancing our mission to deliver
innovative dermatological solutions to our customers. We are
confident that these amended terms will provide us with the
flexibility to execute our strategic initiatives and drive
long-term value for our stakeholders.”
The Company has filed a copy of the amendment on Form 8k on
February 21, 2024.
About STRATA Skin Sciences, Inc.STRATA Skin
Sciences is a medical technology company dedicated to developing,
commercializing, and marketing innovative products for the
in-office treatment of various dermatologic conditions such as
psoriasis, vitiligo, and acne. Its products include the XTRAC®
excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne
Therapy System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership Program.
STRATA’s popular partnership approach includes a fee per treatment
cost structure versus an equipment purchase, installation and use
of the device, on-site training for practice personnel, service and
maintenance of the equipment, dedicated account and customer
service associates, and co-op advertising support to help raise
awareness and promote the program within the practice.
About MidCap FinancialMidCap Financial is a
middle-market focused, specialty finance firm that provides senior
debt solutions to companies across all industries. As of December
31, 2023, MidCap Financial provides administrative or other
services for over $50 billion of commitments*. MidCap Financial is
managed by Apollo Capital Management, L.P., a subsidiary of Apollo
Global Management, Inc, pursuant to an investment management
agreement. Apollo had assets under management of approximately $651
billion as of December 31, 2023, in credit, private equity and real
assets funds.
For more information about MidCap Financial, please visit
http://www.midcapfinancial.com.
For more information about Apollo, please visit
http://www.apollo.com.
*Including commitments managed by MidCap
Financial Services Capital Management LLC, a registered investment
adviser, as reported under Item 5.F on Part 1 of its Form ADV
Safe HarborThis press release includes
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not
limited to the Company’s plans, objectives, expectations and
intentions and may contain words such as “will,” “may,” “seeks,”
and “expects,” that suggest future events or trends. These
statements, the Company’s ability to launch and sell an acne
treatment device and to integrate that device into its product
offerings, the Company’s ability to develop, launch and sell
products recently acquired or to be developed in the future, the
Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from the
coronavirus, fiscal, and political factors, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the
Company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all these forward-looking
statements may prove to be incorrect or unreliable. The statements
in this press release are made as of the date of this press
release, even if subsequently made available by the Company on its
website or otherwise. The Company does not undertake any obligation
to update or revise these statements to reflect events or
circumstances occurring after the date of this press release. The
Company urges investors to carefully review
its SEC disclosures available at www.sec.gov
and www.strataskinsciences.com.
Investor Contact:Rich
CockrellCG CapitalPhone: +1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 4 2024 まで 5 2024
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 5 2023 まで 5 2024